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OBJECTIVES We studied the outcomes of pediatric patients diagnosed with dilated cardiomyopathy
(DCM) and their relation to epidemiologic and echocardiographic variables at the time of
presentation.
BACKGROUND The outcome of pediatric DCM patients ranges from recovery to a 50% to 60% chance of
death within five years of diagnosis. The impact of heart transplantation and other emerging
therapies on the outcomes of pediatric DCM patients is uncertain.
METHODS We performed a retrospective study of the outcomes in 91 pediatric patients diagnosed with
DCM from 1990 to 1999. Routine therapy included use of digoxin, diuretics, angiotensin-
converting enzyme inhibitors, and heart transplantation.
RESULTS At the time of last follow-up, 11 patients (12%) had died without transplantation; 20 (22%)
underwent transplantation; 27 (30%) had persistent cardiomyopathy; and 33 (36%) had
recovery of left ventricular systolic function. Overall actuarial one-year survival was 90%, and
five-year survival was 83%. However, actuarial freedom from “heart death” (death or
transplantation) was only 70% at one year and 58% at five years. Multivariate analysis found
age 1 year (hazard ratio 7.1), age 12 years (hazard ratio 4.5), and female gender (hazard
ratio 3.0) to be significantly associated with a greater risk of death or transplantation and a
higher left ventricular shortening fraction at presentation (hazard ratio 0.92), with a slightly
decreased risk of death or transplantation.
CONCLUSIONS Pediatric DCM patients continue to have multiple outcomes, with recovery of left ventricular
systolic function occurring most frequently. Utilization of heart transplantation has led to
improved survival after the diagnosis of pediatric DCM. (J Am Coll Cardiol 2004;44:
391–7) © 2004 by the American College of Cardiology Foundation(
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Nlthough progress has been made in understanding the
ultiple infectious, metabolic, and myocardial protein mu-
ation etiologies that result in a diagnosis of pediatric dilated
ardiomyopathy (DCM) (1,2), the prognosis of DCM in
nfants, children, and adolescents has been guarded, with
ve-year survival reported to be no 64% (3–6). In the St.
ouis area, survival after the diagnosis of DCM two decades
go was only 50% (7,8). These results led some institutions
o recommend early consideration of heart transplantation
or pediatric DCM (3–5,7).
The decision to proceed with heart transplantation for
ediatric DCM is complicated by the possibility that these
atients can demonstrate eventual improvement and reso-
ution of left ventricular (LV) dilation and dysfunction
From the Departments of *Pediatrics and †Biostatistics, Washington University
chool of Medicine, and ‡Department of Pediatrics, St. Louis University School of
edicine, St. Louis, Missouri; §Department of Pediatrics, University of Miami
chool of Medicine, Miami, Florida; Department of Pediatrics, Baylor University
chool of Medicine, Houston, Texas; ¶Department of Pediatrics, Harvard Medical
chool, Boston, Massachusetts; and #Department of Pediatrics, Vanderbilt University
chool of Medicine, Nashville, Tennessee. This work was supported in part by RO1
L53392 and P50HL61006 from the National, Heart, Lung, and Blood Institute,
epartment of Health and Human Services, NIH, Bethesda, Maryland.
Manuscript received December 16, 2003; revised manuscript received February 25,P004, accepted April 6, 2004.4,5,9). Besides heart transplantation, other new therapies
uch as metabolic component supplementation (10),
ngiotensin-converting enzyme (ACE) inhibition (11), and
ost recently beta-blockade (12) have been utilized as
herapy that may also affect outcome and/or improvement in
V structure and function.
This study was done to delineate the recent course and
ultiple outcomes of pediatric DCM patients when heart
ransplantation was routinely used as a final therapeutic
ption and to determine if there were identifiers at the time
f presentation that could determine which patients will
ecover cardiac function and which patients will require
ransplantation for survival.
ETHODS
atient population. Data for this review were collected
ith the approval of the Committees on Human Research
t St. Louis Children’s Hospital and Cardinal Glennon
hildren’s Hospital, St. Louis, Missouri. Data were primar-
ly collected using standardized collection forms of the
orth American Pediatric Cardiomyopathy Registry (13).
atients were eligible for the study if they were21 years of
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Outcomes of Pediatric Dilated Cardiomyopathy July 21, 2004:391–7ge and presented either to St. Louis Children’s Hospital or
ardinal Glennon Children’s Hospital between January 1,
990, and December 31, 1999, with a diagnosis of DCM.
atients with structural congenital heart disease, valvular
eart disease, arrhythmia-induced cardiomyopathy, and sec-
ndary cardiomyopathies, as a result of endocrine, renal, or
ncologic (anthracycline toxicity) etiology, were excluded.
yocarditis was diagnosed if either endomyocardial biopsy
r autopsy results fulfilled the Dallas criteria (14), or if the
ardiomyopathy was associated with a prodromal viral
llness and evidence of positive viral cultures or rising viral
erologic titers on follow-up.
atient variables. We retrospectively collected epidemio-
ogic and clinical data recorded at the time of presentation.
tiologic work-up to search for myocarditis and/or genetic
r metabolic cardiomyopathy included a thorough family
istory of myocardial disease; genetic, infectious, and met-
bolic testing; and occasionally endomyocardial biopsy.
edications begun within two weeks of presentation were
ecorded as diuretics, digoxin, ACE inhibitors, anti-
rrhythmic agents, intravenous gamma globulin (IVGG), or
eta-blockers. Critical illness at the time of presentation
equiring admission to the intensive care unit (ICU), with
se of intravenous inotropic support or mechanical circula-
ory assistance, was recorded. M-mode echocardiographic
ata consisted of left ventricular shortening fraction (LVSF),
eft ventricular end-diastolic dimension (LVEDD), left ven-
ricular end-systolic dimension (LVESD), LV volume, and
V posterior wall and septal thicknesses. We analyzed LVSF
s a raw value, but converted LV dimensions and wall thick-
esses to the body surface area-appropriate z scores for analysis.
ilated cardiomyopathy was defined by the presence of LVSF
r left ventricular ejection fraction (LVEF) 2 SD above the
ormal mean value for age and LVEDD or LV volume z score
f 2.
Patients were followed yearly after presentation. Data on
utcome, medications, and echocardiographic variables
ere recorded at each examination.
utcomes. Death, heart transplantation, recovery of LV
ystolic function, and persistent cardiomyopathy were the
rimary outcomes of interest. We also created a composite
utcome termed “heart death,” which combined patients
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CI  confidence interval
DCM  dilated cardiomyopathy
ICU  intensive care unit
IVGG  intravenous gamma globulin
LV  left ventricular
LVEDD  left ventricular end-diastolic dimension
LVEF  left ventricular ejection fraction
LVESD  left ventricular end-systolic dimension
LVSF  left ventricular shortening fractionho died or underwent heart transplantation. During 1ollow-up, LV systolic function was determined to have
ecovered when LVSF fell within 2 SD of the mean value
or body surface area. The indications for heart transplan-
ation over the recruitment period were generally intractable
ardiac failure leading to dependence on inotropic medica-
ions, growth failure, or both, and were consistent with
merican Heart Association guidelines (15).
tatistical analysis. Median values and ranges were calcu-
ated for all nonparametric data that did not follow a normal
istribution, whereas mean values  SD were calculated for
arameters with normal distribution. Normality of the
istribution was assessed by inspection of plots, including
tem-and-leaf, box, and normal scores plots. The time-to-
vent data were not assumed to be normally distributed. We
sed the Kaplan-Meier product limit method, which does
ot assume an underlying form for the data. The SAS
rogram (SAS Institute, Cary, North Carolina) calculated
he corresponding estimates of the standard error, using
reenwood’s formula (16). A standard normal distribution
s used to put the confidence interval (CI) on the time-to-
vent curve. Comparison of patient variables among patient
utcomes was performed with the Fisher exact test for
ategorical variables and the Wilcoxon/Mann-Whitney U
est for continuous variables. Univariate analysis of patient
ariables related to outcome was performed using the
aplan-Meier limit method, in conjunction with Cox pro-
ortional hazards analyses. Multivariate Cox proportional
odels were created based on the results of the univariate
nalyses. A value of p 0.05 was utilized as the criterion for
tatistical significance. Analysis was carried out in SAS
ersion 8.1. Standard SAS procedures, in particular, proc
ifetest and proc phreg, were utilized. Models were validated
sing standard diagnostics, such as deviance on the basis of
linical significance, and model fit was assessed using plots
nd measures of information, such as Akaike’s information
riterion.
ESULTS
atient population and presentation. We identified 91
hildren who were diagnosed with DCM between the
eginning of 1990 and the end of 1999 (Table 1). The age
anged from birth to 18 years; 23 (25%) were1 year of age
t presentation, 53 (48%) were between 1 and 12 years of
ge, and 25 (27%) were over 12 years of age. Almost
our-fifths (79%) of the children presented with symptoms
f congestive heart failure, and 35% underwent ICU admis-
ion at the time of presentation. The other children were
dentified during evaluation of a heart murmur, observation
f cardiomegaly on a chest radiograph, or evaluation because
f a family history of cardiomyopathy. One family had two
hildren in the group; both experienced symptomatic heart
ailure during the study period. No other multiple family
embers with DCM were included in the subject group. A
pecific etiology for DCM was made in 39.5% (myocarditis
3%, dystrophin gene defect 12%, familial [history of at
l
b
c
l
m
d
5
n
o
s
a
1
(
e
m
m
d
P
o
t
t
O
b
O
t
d
d
u
t
v
f
w
w
p
t
p
A
r
s
a
w
(
t
w
o
m
d
d
c
h
h
fi
d
a
o
s
d
p
R
D
d
2

t
t
a
H
g
e
w
a
w
a
s
i
e
L
w
r
T
M
M
C
A
P
E
M
*
393JACC Vol. 44, No. 2, 2004 Tsirka et al.
July 21, 2004:391–7 Outcomes of Pediatric Dilated Cardiomyopathyeast two family members] cardiomyopathy 9%, and meta-
olic disorders 5.5%). Metabolic disorders included mito-
hondrial myopathies (n 3), Barth syndrome (n 1), and
ong-chain fatty acid breakdown disorder (n  1). Endo-
yocardial biopsies were performed within two weeks of
iagnosis in 23 patients: 9 were diagnostic for myocarditis,
revealed endocardial fibroelastosis, and the other 9 showed
onspecific findings.
Treatment with ACE inhibitors was administered to 73%
f patients within two weeks of diagnosis and to 86% of the
ubgroup of patients with congestive heart failure. Digoxin
nd diuretics were instituted with a similar frequency. After
994, IVGG was given per the protocol of Drucker et al.
17) for a clinical suspicion of myocarditis, often before
ndomyocardial biopsy. Three patients were placed on
echanical circulatory support (two with extracorporeal
embrane oxygenation and one with a ventricular assist
evice) at the time of presentation.
atient outcomes. At the most recent follow-up, 11 (12%)
f the 91 children died and did not receive a transplant. Of
hese 11 children, 4 had severe Duchenne’s muscular dys-
rophy and were not considered heart transplant candidates.
f the 20 (22%) who underwent heart transplantation, all
ut 4 were receiving inotropic support (United Network for
rgan Sharing [UNOS] status 1) at the time of transplan-
ation. Thus, 31 patients (34%) had a “heart death.” Evi-
ence of persistent cardiomyopathy was found in 27 chil-
able 1. Patient Characteristics at Presentation (n  91)
edian age (range) at presentation (yrs) 5.1 (0–17.8)
ale gender 58 (64%)
aucasian 64 (70%)
frican American 25 (27%)
resentation characteristics
Congestive heart failure 72 (79%)
ICU admission at presentation 32 (35%)
Arrhythmia 3 (3%)
Asymptomatic 16 (18%)
tiology of dilated cardiomyopathy
Myocarditis 12 (13%)
Dystrophin gene defects 11 (12%)
Familial 8 (9%)
Metabolic 5 (5.5%)
Idiopathic 55 (60.5%)
edications initiated within 2 weeks of presentation
Digoxin
All patients 78 (86%)
With heart failure 69 (96%)
Diuretics
All patients 68 (75%)
With heart failure 63 (87%)
ACE inhibitors
All patients 66 (73%)
With heart failure 62 (86%)
IVGG*
All patients 21 (23%)
With heart failure 21 (29%)
Intravenous gamma globulin (IVGG) used after 1994.
ACE  angiotensin-converting enzyme; ICU  intensive care unit.ren (30%) at their last follow-up, none of whom had indergone transplantation. Recovery of LV systolic func-
ion (improvement of LVSF within 2 SD from the mean
alue of the standardized population) at the time of last
ollow-up occurred in 33 children (37%). When patients
ith myocarditis were excluded from the analysis, there
ere similar proportions of patients with heart death (36%),
ersistent cardiomyopathy (30%), and recovery of LV sys-
olic function (34%).
Within the first year after diagnosis, 90% of the trans-
lantations and 64% of the deaths occurred (Fig. 1).
lthough the majority (57%) of children who underwent
ecovery of LV systolic function did so in the first year, a
ubstantial proportion returned to normal up to six years
fter presentation. Three of the seven children who died
ithin a year of presentation were UNOS status 1
inotrope-dependent) heart transplant candidates at the
ime of death. Two died in cardiogenic shock associated
ith multi-organ failure that precluded transplantation, and
ne was not considered for heart transplantation due to
uscular dystrophy. One patient with idiopathic DCM
ied suddenly two years after presentation. The three late
eaths, at five, six, and eight years after presentation, were in
hildren with muscular dystrophy who were not considered
eart transplant candidates. All three died with intractable
eart failure associated with atrial flutter (n  1) or
brillation (n  2).
Actuarial survival of the children from the time of
iagnosis was 90% at one year (82 of 91) and 83% (76 of 91)
t five years (Fig. 2). Death after transplantation has not
ccurred in this cohort, and no child with recovery of LV
ystolic function has died. Freedom from “heart death”
ecreased from 70% at one year to 58% at five years after
resentation (Fig. 3).
elation of outcomes to characteristics at presentation.
ifferent age groups at the time of presentation had
ifferent frequencies of outcomes during follow-up (Table
). Fifty-seven percent of children presenting with DCM at
1 year of age and 47% presenting at 12 years of age at
he time of diagnosis had a heart death, whereas 49% of
hose children who were diagnosed with DCM between 1
nd 12 years of age had recovery of LV systolic function.
owever, there were considerable proportions of each age
roup among the various outcome groups (Table 2). Recov-
ry of LV systolic function occurred in 48% of children
hose diagnosis occurred in conjunction with admission to
n ICU. However, recovery also occurred in 23% of patients
hose diagnosis did not occur in conjunction with an ICU
dmission.
Median baseline z scores for LVEDD and LVESD were
ignificantly higher in patients with heart death and signif-
cantly lower in patients whose LV systolic function recov-
red to normal. The opposite was true for median baseline
VSF values, which were significantly lower in patients
ith heart death and significantly higher in patients with
ecovery of LV systolic function. The large overlap of
ndividual echocardiographic variables among the outcome
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Outcomes of Pediatric Dilated Cardiomyopathy July 21, 2004:391–7roups negated correlating an individual patient’s outcome
ith LV size and systolic function at the time of presenta-
ion, despite the significant differences in echocardiographic
ariables for the outcome groups as a whole. Race, family
istory of cardiomyopathy, presence of congestive heart
ailure, etiology of cardiomyopathy, presence of arrhythmia,
r use or non-use of any particular medication did not differ
ignificantly among the outcome groups.
igure 1. Time to outcome after presentation among 91 children with
transplantation, recovery, or death) is shown as a function of year of follo
ransplantation, died, or had recovery of left ventricular systolic function.
atients available for follow-up at the given time interval.
igure 2. Overall survival for 91 children with dilated cardiomyopathy (95
atients alive at the end of the study.isk factors for outcome. Univariate analysis identified
emale gender (p  0.02), age 1 year (p  0.002), age
12 years (p  0.006), lower LVSF z scores (p  0.006),
nd higher LVESD z scores (p  0.03) as variables at
resentation significantly associated with death or trans-
lantation. Admission to an ICU at the time of diagnosis (p
0.017) was, interestingly, significantly associated with
ecovery of systolic function.
ed cardiomyopathy. The percentage of patients with a given outcome
Patients are censored from ongoing follow-up once they have undergone
the figure represents new outcomes that occurred in the cardiomyopathy
nfidence bands are shown). Last follow-up times are indicated by “” fordilat
w-up.
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July 21, 2004:391–7 Outcomes of Pediatric Dilated CardiomyopathyMultivariate analysis identified no variables that predicted
return to normal systolic function. Hazards ratios for
ncreased risk of death or transplantation were 7.1 (95% CI
.6 to 19.2) for age 1 year, 4.5 (95% CI 1.6 to 12.7) for
ge 12 years, and 3.0 (95% CI 1.4 to 6.2) for female
ender. Higher LVSF at presentation was associated with a
light decreased risk of death or transplantation (odds ratio
.92, 95% CI 0.87 to 0.98).
ISCUSSION
ecent epidemiologic studies in Australia and the U.S. have
ound pediatric DCM to occur with an incidence of 1.13 to
.24 per 100,000 children (1,2). Pediatric DCM has mul-
iple causes, including infection, mutations of myocardial
ytoskeletal and structural proteins, and disorders of myo-
ardial metabolism. Although most cases of pediatric DCM
re idiopathic, diagnostic algorithms (18) have increased the
roportion of pediatric DCM cases with a known cause.
his trend is reflected in our study, in which a cause of
CM was identified in nearly 40% of children.
Pediatric DCM may have any of several outcomes.
eported five-year survival rates range between 50% and
0% (3–8). These grim statistics have led investigators to
ecommend early consideration of heart transplantation for
hese children (3–5,7). Cardiac transplantation was rou-
igure 3. Freedom from “heart death” (death or heart transplantation) in 9
ollow-up times are indicated by “” for patients alive at the end of the s
able 2. Significant Dilated Cardiomyopathy Patient Characteris
Presentation
Age (yrs) ICU Admissi
<1 1–12 >12 Yes N
Value 0.0048* 0.0219*
ecovery 26% 49% 16% 48% 23
yopathy 17% 33% 37% 31% 28
eart death 57% 18% 47% 21% 49
Fisher exact test. †Wilcoxon-Mann-Whitney U test.
ICU  intensive care unit; LVEDD and LVESD  left ventricular end-diastolic andinely used as a final therapeutic strategy for our patients,
nd these children had a five-year survival rate of more than
0%. Additional therapies were also utilized in this group
efore transplantation, which may have contributed to
mproved outcome. The use of ACE inhibitors has been
eported to be associated with improvement of LV dysfunc-
ion in children (11,19). Larger adult studies, however, have
ot noted improvement, but inhibition of progression of LV
ilation and dysfunction with ACE inhibitor administration
20). Preliminary evidence indicates that beta-blocker ther-
py can improve LV dysfunction in pediatric DCM (21).
etrospective studies have suggested that administration of
VGG leads to improvement of LV dysfunction in pediatric
V systolic dysfunction thought to be due to myocarditis
17), but those results were not replicated in a randomized,
lacebo-controlled study in adults with acute-onset DCM
22). Refinements in critical care and inotropic support
ndoubtedly improved the survival rate of patients who were
ritically ill in an ICU and also helped end-stage patients to
urvive until transplantation. Two of the three patients
laced on mechanical support ultimately survived: one with
esidual cardiomyopathy and one whose LV systolic func-
ion recovered. However, the proportions of patients who
ither died or received a transplant (those who had a heart
eath) were similar to previous, older outcome studies.
dren with dilated cardiomyopathy (95% confidence bands are shown). Last
t Presentation That Were Associated With a Specific Outcome
Median LVEDD
z Score
(Range)
Median LVESD
z Score
(Range)
Median LVSF
Raw Score
(Range)
0.0080† 0.0005† 0.0033†
2.20 (2.00–5.80) 3.86 (1.41–8.87) 18% (5–32%)
3.12 (2.00–5.55) 6.49 (2.11–9.72) 13% (6–30%)
3.48 (2.00–7.90) 7.50 (2.07–12.36) 10.5% (4–26%)1 chiltics a
on
o
%
%
%-systolic diameter, respectively; LVSF  left ventricular shortening fraction.
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Outcomes of Pediatric Dilated Cardiomyopathy July 21, 2004:391–7hus, it would appear the primary factor that improved
urvival in this group of pediatric DCM patients was heart
ransplantation.
The limited donor pool for heart transplantation and the
otential for recovery of LV dysfunction make identification
f profiles that lead to either death or transplantation versus
ecovery of function of critical importance for patients with
ediatric DCM. Poorer initial LVSF in this study was only
ildly associated with a greater risk of death or transplan-
ation and correlates with similar findings in the National
ustralian Childhood Cardiomyopathy Study (6). Al-
hough median LVSF at presentation differs significantly
mong the outcome groups, the large overlap of values
recludes using this and other echocardiographic variables
s predictors for clinical decision-making. Furthermore,
evere illness on presentation leading to ICU admission was
ssociated with patients who recovered their LVEF on
ollow-up. These findings are consistent with patients who
resent with “fulminant myocarditis,” who tend to have
ood outcomes despite critical illness at the time of presen-
ation (23).
Age 1 year or 12 years was associated with an
ncreased risk of death or transplantation in this cohort.
hese findings are similar to the age-specific determinants
f outcome in pediatric DCM in a recent Finnish
opulation-based study (5). Older studies relating age of
resentation to outcome with pediatric DCM have given
onflicting results (3,4,7,8,24,25). The substantial propor-
ions of infants and adolescents who recover their LVEF or
o not die or undergo transplantation make age-specific
redictors of outcome difficult to apply to direction of
herapies like heart transplantation. The group of patients
ge 1 to 12 years at presentation not only had a smaller
roportion die or undergo transplantation, but also had a
reater proportion who recovered their LVEF, as compared
ith the infant and adolescent groups. This group of
hildren conceivably may have had a greater proportion of
CM due to myocarditis, compared with the known
endency toward many lethal metabolic cardiomyopathies to
resent in infancy (26) and the tendency toward cardiomy-
pathies due to dystrophin mutations to present in adoles-
ence.
In our study, female gender was found to be a poor
redictor of outcome. The reason for this result is uncertain.
emale gender has been associated with late cardiomyopa-
hies in anthracycline-treated survivors of childhood cancer
27). However, young adult women with idiopathic DCM
ave been reported to have a poor outcome (28). One study
f adult DCM patients found high soluble interleukin-2
eceptor serum levels, a measure to T-lymphocyte activa-
ion, to be associated with poorer ejection fractions and
ardiac output and to occur more frequently in female
atients (29). Further study is needed to confirm this
nding and to investigate potential immunologic or hor-
onal factors that may contribute to this phenomenon.
Our results confirm those of earlier studies, which have iound that most major clinical events occur within one year
f presentation (3,5,25). The high proportion of deaths or
ransplantation that occurred within one year after presen-
ation suggests many patients with pediatric DCM, even
hose without a multi-system metabolic disease, are not
iagnosed until they have end-stage disease that is not
ffectively palliated with the medical therapies used to treat
hem.
tudy limitations. This study, although as large as or
arger than previous outcome studies of pediatric DCM,
uffers from a relatively small sample size that limits iden-
ification of risk factors for outcome. Follow-up of the
atient population is short and cannot address the long-
erm outcomes of patients who receive a transplant, have
ersistent cardiomyopathy, or show recovery of LVEF. The
ge distribution of this cohort of patients does not reflect the
nding of large epidemiologic studies that most pediatric
CM cases are diagnosed in infancy (1,2). This difference
n age distribution may reflect a decreased ascertainment of
nfantile DCM in our referral region in the 1990s, or simply
ay be due to chance. The cohort had a higher percentage
f DCM cases diagnosed with a specific etiology, compared
ith population-based studies, with a greater proportion of
ardiomyopathies due to dystrophin mutations (1,2). The
resence of a large, national muscular dystrophy center at
ashington University may explain the presence of these
henomena in this patient population.
This study’s retrospective design further limits the num-
er of variables to be studied. In addition, although diag-
ostic evaluations and initial therapeutic strategies were
imilar among the group, a standardized evaluation and
herapeutic protocol were not followed within the group.
ultiple physicians initiated, manipulated, and terminated
herapy in different ways. This limitation prevented study-
ng the effects of when and how cardiac medications were
anipulated or terminated in relation to the outcomes.
onclusions. Despite these limitations, this study never-
heless illustrates the improvement of survival in infants,
hildren, and adolescents diagnosed with pediatric DCM
ffered by routine use of heart transplantation. Pediatric
eart transplantation, however, is a time-limited therapy,
ith a currently estimated half-life of 13 years for a pediatric
ardiac allograft (30). Furthermore, pediatric donor organs,
specially for infant recipients, are scarce, and substantial
umbers of potential pediatric recipients die before receiving
n organ (31).
The potential for routine use of beta-blockade (32),
esynchronization therapy (33), or statin therapy (34) to
otentiate ventricular remodeling, improve survival, and
revent or delay transplantation remains to be fully evalu-
ted in the pediatric population. Refinements in the diag-
osis of myocarditis may improve prognostication of out-
omes and potentially determine application of immuno-
uppressive/modulating therapy (35). The limitations of
eart transplantation as therapy for pediatric DCM make itmperative that application of these new therapies for the
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f pediatric DCM.
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